Critical Partners on FDA's Critical Path
This article was originally published in RPM Report
Executive Summary
The new C-Path Institute in Tucson, Arizona sits at the heart of FDA's intentions to moderize the drug development process. It has three foundling partners: the Institute (which came out of the existing CERT at the University of Arizona), FDA and SRI. These are the key people in the partnership.
You may also be interested in...
Critical Collaborators
The Food & Drug Administration's dream of identifying a "critical path" to improve drug development productivity is one step closer to moving from rhetoric to reality. Three months after the official blessing from the Department of Health & Human Services for an effort by the C-Path Institute (in Tucson, Arizona) to create a consortium to validate preclinical toxicity test methods, C-Path has signed on nearly a dozen willing participants from big pharma.
Critical Collaborators
The Food & Drug Administration's dream of identifying a "critical path" to improve drug development productivity is one step closer to moving from rhetoric to reality. Three months after the official blessing from the Department of Health & Human Services for an effort by the C-Path Institute (in Tucson, Arizona) to create a consortium to validate preclinical toxicity test methods, C-Path has signed on nearly a dozen willing participants from big pharma.
Von Eschenbach to Stay at FDA
FDA Commissioner Andrew von Eschenbach is poised to remain head of the agency, either in an acting role or as the White House nominee, through the end of the second Bush term. Other candidates were interviewed-including drug safety expert Ray Woosley, MD, but the administration appears to be happy with the job the National Cancer Institute Director is doing.